Do you have the same question? Follow this Question
Oct 01, 2025 - 05:53 AM
We’ve provided several answers to questions related to Harvoni (Ledipasvir/Sofosbuvir) , see some other helpful Q&A related to this product.
Question: What are the ChEBI identifiers for the components?
Answer: The ChEBI identifiers are 85089 and 85083, offering insights into the chemical properties and biological roles of the components.
Question: How is the medication administered?
Answer: The medication is administered orally, which is convenient and non-invasive, making it easier for patients to comply with treatment.
Question: What is the recommended treatment for genotype 1, treatment-naive patients?
Answer: For genotype 1, treatment-naive patients, the medication is recommended alone for 12 weeks, offering a streamlined treatment plan.
Question: What is the protein binding percentage for the medication?
Answer: The protein binding is greater than 99.8% for one component and 61-65% for the other, affecting how the drug is distributed in the body and its therapeutic effects.
Question: What is the bioavailability of the medication?
Answer: The bioavailability is 76%, meaning that 76% of the drug enters the circulation when introduced into the body, making it highly effective in treating hepatitis C.
View all Harvoni (Ledipasvir/Sofosbuvir) Questions & Answers
